GLP-1 receptor agonists are a class of peptides that mimic a naturally occurring gut hormone. Researchers and clinicians have studied them extensively for their effects on blood sugar and body weight. Their gastrointestinal side effects, including nausea, vomiting, and slowed stomach emptying, are well documented in the literature. What was not documented until recently is a far rarer and more severe complication: a full-thickness rupture of the esophagus.
A case report published in the Journal of Cardiothoracic Surgery describes what the authors call the first documented instance of Boerhaave's syndrome associated with GLP-1 receptor agonist use. Boerhaave's syndrome is a spontaneous, transmural perforation of the esophagus, meaning the tear goes through every layer of the esophageal wall. It is a life-threatening emergency under any circumstances. This report is significant not only because of the severity of the event, but because of the specific circumstances that preceded it: a patient restarting a GLP-1 receptor agonist at a high dose, without dose titration, after several months off therapy.
The case is a single patient report, not a clinical trial, so it cannot establish causation or tell us how often this might occur. What it does offer is a detailed account of the sequence of events, the clinical management required, and a hypothesis about the underlying mechanism. For anyone interested in how peptides interact with physiology, and what can go wrong when physiological stress is pushed to an extreme, this report raises genuinely important questions.
What happened in the reported case
The patient was a previously healthy woman in her 50s who had used a GLP-1 receptor agonist, specifically semaglutide, for weight management. After several months off the medication, she restarted it at the maximum approved weekly dose of 2.4 milligrams. Critically, she did not follow a gradual dose-escalation schedule. The very next day, she developed severe nausea, repeated vomiting, and acute chest pain.
She arrived at the hospital in vasopressor-dependent shock, meaning her blood pressure had dropped so severely that she required medication to keep her cardiovascular system functioning. She also needed mechanical ventilation for respiratory failure. Imaging showed air in the mediastinum, the space between the lungs, along with fluid accumulation in both pleural cavities. An esophagram, a contrast imaging study of the esophagus, confirmed a contained perforation of the esophageal wall.
The initial management was non-surgical. Clinicians placed an endoscopic stent to seal the perforation site, inserted a nasojejunal feeding tube to bypass the esophagus entirely, and drained the fluid from around the lungs via chest tubes. The patient improved and was eventually discharged.
A serious setback two months later
The case did not end at discharge. Two months after her initial hospitalization, the patient was readmitted. She had developed necrotizing pneumonia, a particularly destructive form of lung infection. Imaging and endoscopy revealed an esophagopleural fistula, which is an abnormal channel connecting the esophagus to the pleural space, along with an abscess and a stent that had migrated from its original position.
At this point, surgical intervention became necessary. Surgeons performed a left thoracotomy, which involves opening the chest through the left side, then drained the abscess, performed a decortication to remove infected tissue from the lung lining, and completed a wedge resection to remove the portion of lung tissue that had become necrotic. The site of the original perforation was reinforced using an intercostal muscle flap, a technique that uses nearby tissue to provide structural support. A percutaneous endoscopic gastrostomy tube was placed to allow continued nutritional support.
At a 10-month follow-up, the patient was eating a regular diet, the gastrostomy tube had been removed, and endoscopic examination confirmed that the esophagus had healed. The authors noted that she was advised to permanently discontinue GLP-1 receptor agonists.
The proposed mechanism
The authors offer a mechanistic hypothesis for how this sequence of events may have unfolded. GLP-1 receptor agonists are known to slow gastric emptying, a condition referred to as gastroparesis when it becomes significant. When the stomach empties slowly, food and fluid accumulate, creating pressure and increasing the likelihood and forcefulness of any subsequent vomiting.
Boerhaave's syndrome, in its classical form, results from a sudden, dramatic spike in intraluminal esophageal pressure, most often caused by forceful vomiting against a closed glottis. The authors suggest that GLP-1-induced gastroparesis created the conditions for exactly this kind of forceful emesis, and that the resulting pressure exceeded what the esophageal wall could withstand.
The case also draws attention to the dose-titration issue. Standard prescribing practice for GLP-1 receptor agonists involves starting at a low dose and gradually increasing it over several weeks. This approach is designed to allow the body to adapt to the gastrointestinal effects. The patient in this report skipped that process entirely, jumping directly to the highest available dose after a prolonged break. The authors suggest this may have produced an especially intense gastroparesis effect, amplifying the risk.
Context within existing literature
The gastrointestinal side effect profile of GLP-1 receptor agonists is not new territory. Published trial data and post-marketing surveillance have consistently identified nausea, vomiting, diarrhea, and constipation as common adverse effects. More serious gastrointestinal complications, including pancreatitis and ileus, have also been described in the literature, though they occur at much lower frequencies.
Mucosal injuries such as Mallory-Weiss tears, which are partial-thickness lacerations at the gastroesophageal junction caused by repeated vomiting, had previously been reported in connection with GLP-1 receptor agonist use. A Mallory-Weiss tear is serious, but it does not penetrate all the way through the esophageal wall. The case described in this report goes several steps further, representing a complete transmural rupture, which is categorically more dangerous.
The authors characterize this as the first documented case of Boerhaave's syndrome linked to GLP-1 receptor agonist use. Given how widely these peptides are now prescribed, the authors argue that clinicians should keep this complication in mind when evaluating patients who present with chest pain and vomiting in the context of GLP-1 receptor agonist use or recent reinitiation.
Limitations and what this single case can and cannot tell us
A single case report occupies the lowest tier of clinical evidence. It cannot establish that GLP-1 receptor agonists cause esophageal perforation in any generalizable sense. It cannot provide an incidence rate, identify which patients are at higher risk, or confirm that the drug was the proximate cause rather than a contributing factor in an unusual constellation of circumstances.
What a case report can do is document a previously undescribed clinical event, propose a plausible biological mechanism, and alert the broader research and clinical community to look for similar cases. The value here lies in that documentation and in the hypothesis it generates. Future case series, pharmacovigilance data, or prospective observational studies would be needed to understand whether this represents a genuinely rare idiosyncratic event or a signal worth monitoring more closely.
The authors conclude with a call for early multidisciplinary management in any patient presenting with this symptom cluster during GLP-1 receptor agonist initiation or reinitiation. They also emphasize the importance of dose titration protocols, particularly after a prolonged interruption in therapy, as a potential safeguard against the kind of rapid, severe gastroparesis that the literature suggests may have contributed to this event.
